Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy.
Sanaz Eftekhari, Jafar Mehvari Habibabadi, Massoumeh Najafi Ziarani, Seyed Sohrab Hashemi Fesharaki, Marzieh Gharakhani, Hossein Mostafavi, Mohammad Taghi Joghataei, Nahid Beladimoghadam, Elham Rahimian, Mahmoud Reza Hadjighassem
Cellular and Molecular Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Epilepsia 2013 JanAlterations in the balance of K-Na-2Cl cotransporter (NKCC1) and Na-Cl cotransporter (KCC2) activity may cause depolarizing effect of γ-aminobutyric Acid (GABA), and contribute to epileptogenesis in human temporal lobe epilepsy. NKCC1 facilitates accumulation of chloride inside neurons and favors depolarizing responses to GABA. In the current pilot study we provide the first documented look at efficacy of bumetanide, a specific NKCC1 antagonist, on reduction of seizure frequency in adult patients with temporal lobe epilepsy. According to our results, seizure frequency was reduced considerably in these patients. Furthermore, epileptiform discharges decreased in two of our patients. If the efficacy of bumetanide is proven in large scale studies, it can be used as a supplemental therapy in temporal lobe epilepsy. Wiley Periodicals, Inc. © 2012 International League Against Epilepsy.
Citation
Sanaz Eftekhari, Jafar Mehvari Habibabadi, Massoumeh Najafi Ziarani, Seyed Sohrab Hashemi Fesharaki, Marzieh Gharakhani, Hossein Mostafavi, Mohammad Taghi Joghataei, Nahid Beladimoghadam, Elham Rahimian, Mahmoud Reza Hadjighassem. Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy. Epilepsia. 2013 Jan;54(1):e9-12
Mesh Tags
Substances
PMID: 23061490
View Full Text
